Twilight-specific light cues.
Tarantini G, Fraccaro C.
Catheter Cardiovasc Interv. 2021 Jan 1;97(1):72-73. doi: 10.1002/ccd.29443.
Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study.
Rusinaru D, Vrolix M, Verheye S, Chowdhary S, Schoors D, Di Mario C, Desmet W, Donohoe DJ, Ormiston JA, Knape C, Bezerra H, Lansky A, Wijns W; DESSOLVE II Investigators.
Catheter Cardiovasc Interv. 2015 Dec 1;86(7):1141-50. doi: 10.1002/ccd.25610. Epub 2015 Sep 22.
A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
de Winter RJ, Katagiri Y, Asano T, Milewski KP, Lurz P, Buszman P, Jessurun GAJ, Koch KT, Troquay RPT, Hamer BJB, Ophuis TO, Wöhrle J, Wyderka R, Cayla G, Hofma SH, Levesque S, Żurakowski A, Fischer D, Kośmider M, Goube P, Arkenbout EK, Noutsias M, Ferrari MW, Onuma Y, Wijns W, Serruys PW.
Lancet. 2018 Feb 3;391(10119):431-440. doi: 10.1016/S0140-6736(17)33103-3. Epub 2017 Dec 5.
[Optimal platelet inhibition after coronary stent implantation. Current status].
Silber S, Hoffmeister HM, Bode C.
Herz. 2008 Jun;33(4):244-53. doi: 10.1007/s00059-008-3138-9.
Therapies targeting inflammation after stent implantation.
Okura H, Takagi T, Yoshida K.
Curr Vasc Pharmacol. 2013 Jul;11(4):399-406. doi: 10.2174/1570161111311040004.
The relation of polymer structure of stent used in patients with acute coronary syndrome revascularized by stent implantation with long-term cardiovascular events.
Yaylak B, Polat F, Onuk T, Akyüz Ş, Çalık AN, Çetin M, Eren S, Mollaalioğlu F, Kolak Z, Durak F, Dayı ŞÜ.
Catheter Cardiovasc Interv. 2023 Dec;102(7):1186-1197. doi: 10.1002/ccd.30881. Epub 2023 Oct 19.
Assessment of Cutting-Balloon Angioplasty with Novel Bioabsorbable Polymer-Coated Everolimus-Eluting Stent in Treating Calcified Coronary Lesions Guided by Intravascular Ultrasound (CUPID Trial): study design and protocol.
Ahn J, Yu H, Park S, Suh J.
Trials. 2024 Oct 29;25(1):727. doi: 10.1186/s13063-024-08484-0.
Coronary artery perforation after bioresorbable scaffold implantation treated with a new generation covered stent-OCT insights.
Chen D, Gadeley R, Wang A, Jepson N.
BMC Cardiovasc Disord. 2022 Feb 23;22(1):66. doi: 10.1186/s12872-022-02501-3.
Targeted therapy with a localized abluminal groove low-dose sirolimus-eluting bioabsorbable polymer coronary stent in chronic total occlusions: The TARGET CTO non-inferiority randomized trial.
Wang G, Zhang R, Chen SL, Wang J, Li Y, Zheng M, Cao R, Ma Y, Sun Z, Li X, Su X, Lu W, Xu Y, Li X, Li Y, Sun F, Han Y; TARGET CTO Investigators.
Am Heart J. 2025 Jul;285:93-104. doi: 10.1016/j.ahj.2025.01.018. Epub 2025 Feb 3.
Bioabsorbable stent quo vadis: a case for nano-theranostics.
Gundogan B, Tan A, Farhatnia Y, Alavijeh MS, Cui Z, Seifalian AM.
Theranostics. 2014 Feb 22;4(5):514-33. doi: 10.7150/thno.8137. eCollection 2014.
